Doxall™ Launch Media Release 8 April 2021

Media Release

For Immediate Distribution

DATE 8th April 2021

 

Australian research during Covid-19 shutdown results in the development & launch of a new antimicrobial technology.

· Highly efficacious sanitisation products with plant-based active ingredients for home and commercial use.

· New sanitiser range aims to improve safety for the community whilst reducing impact on the environment and was developed in Melbourne during the COVID pandemic.

· The products, branded Doxall™, are a result of over 10 years of antimicrobial research.

· The Doxall range includes a Hand Sanitiser, a Surface Cleaner & Sanitiser, and a Therapeutic Goods Administration (TGA) registered Commercial Grade Disinfectant and Cleaner. A Hospital-grade Disinfectant product is under development and is expected to be released within the next several months.

· The technology has also demonstrated exciting results in industrial and commercial applications.

· Doxall™ Commercial Grade Disinfectant kills Covid-19.

· As an R&D-driven company, Doxall™ sales will contribute to ongoing research to counteract the rise of superbugs, which account for more 700,000 deaths globally each year.

 

Wintermute Biomedical, a Melbourne-based research group, has developed a formulation composed of a combination of a fatty acid found in coconut oil and an amino acid found in pumpkin seeds, that demonstrates broad spectrum antimicrobial activity. The formulation was initially under development as a potential antimicrobial therapeutic, where it was shown to have efficacy against a broad range of infectious disease agents, including:

· Influenza B strain Brisbane 60/2008

· Multi drug resistant E. coli

· Rhinovirus 14 strain 1059

· C. difficile (vegetative cells and spores)

· Multidrug resistant Pseudomonas aeruginosa

· Methicillin resistant Staphylococcus aureus (MRSA)

· Streptococcus pneumoniae

· Anthrax (B. atrophaeus and B. anthracis (Sterne)

· Ebola

· Botulism (C. butyricum)

· Pseudomallei (B. thailandensis)

 

During the COVID-19 lockdown the Wintermute research team realised the potential of the formulation as a sanitisation agent, and a new range of cleaning and sanitisation products was developed. The products have been launched under the Doxall™ brand for the consumer market.

 

The Australian household cleaner market is estimated to represent a AU$483M opportunity, while global disinfectant sales are estimated to surpass US$8.6B by 2026.
https://www.statista.com/outlook/cmo/home-laundry-care/household-cleaners/australia?currency=USD
https://www.globenewswire.com/news-release/2020/09/02/2087481/0/en/Surface-Disinfectant-Market-projected-to-surpass-8-5-billion-by-2026-Says-Global-Market-Insights-Inc.html

 

There is significant benefit to consumers as the Doxall™ products are water-based, persist on surfaces after application providing ongoing activity, and have a low toxicity profile, thereby removing potentially harmful and/or flammable chemicals from the home.
Commercial benefits include:
- Effective sanitisation without the need to preclean, post clean or rinse surfaces
- Reduced touch points for cleaning staff
- No special storage or transport requirements
- Risk and liability reduction by removing potentially harmful and/or flammable substances from the work environment

Further development is now underway to qualify the product for high level usage in hospitals.

 

According to Brett Carter, Wintermute Biomedical’s CEO, the Doxall™ product range was developed by the Australian research team during the extended lockdowns experienced in Melbourne.

“Wintermute had been working to develop new therapeutics to address the threat of antimicrobial resistance (AMR) for over ten years,” Brett Carter said.

“Several formulations that were under development showed strong activity against germs and viruses, but there wasn’t a good rationale to divert any of them away from the original therapeutic aims.”

Mr Carter said when the pandemic hit, the team realised that one of its high performance anti-pathogenic formulations, with an incredibly low toxicity profile, could be re-directed into use as a highly effective water-based sanitisation agent. 

Mr Carter pointed out that, before the current pandemic, AMR was regarded as the greatest global health challenge of our time and noted that this is what prompted Dr Thomas Rau, the organisation’s Chief Scientific Officer, to establish Wintermute Biomedical ten years earlier.

AMR occurs when a microorganism becomes resistant to an antimicrobial medicine, such as an antibiotic. Today, an estimated 700,000 people die each year from drug-resistant infections, and more alarmingly, this number is projected to accelerate towards 10 million by 2050, outstripping even cancer (Review on Antimicrobial Resistance, UK Government, 2014).

“In the near future we face the possibility of a post-antibiotic era, where a simple infection could again become deadly. Many medical procedures that we currently take for granted, including surgery and chemotherapy, could become impossible. This is the reason that some of the profits generated by Doxall sales will be directed into further AMR research,” Mr Carter said.

The products will be marketed by a Wintermute subsidiary company, Ten Carbon Chemistry. After the product development, external laboratory testing, and registration by the TGA for the Doxall disinfectant, the move to the Ten Carbon Chemistry subsidiary began to separate the sanitisation activities from Wintermute’s ongoing AMR mission.

“So far there appears to be extensive applications for this new technology. Not only are the products effective in the home and office, but we also have highly encouraging test results from industrial applications, including use within a meat processing facility and within the recycling industry. It’s very dynamic and an exciting time for our team.” Brett Carter said.

The Doxall™ product range is the first commercial foray for the organisation, providing this new technology initially to consumers and businesses in Australia, with plans to expand internationally.

Potential further uses for the technology include food production and processing, animal handling, aviation, international biosecurity management, coatings, and fabric impregnation.

Ten Carbon Chemistry is committed to incorporating a social mission into its vision for the organisation and will invest part of its profits from Doxall™ sales into AMR research. The Doxall™ team believes that achieving a sustainable supply chain, creating products that do not harm communities or the environment, and using some of the organisation’s success to make the world a better place should be the rule, not the exception, in a successful modern business. As its operations grow, Ten Carbon Chemistry will pursue independent certifications that reinforce this mission.

 

Doxall™ is the result of over 10 years of antibacterial research and represents a major scientific advance in cleaning and sanitisation technology. The product range includes:

· Hand Sanitiser – Kills 99.9% germs

· Surface Cleaner & Sanitiser – Kills 99.9% germs

· Household/Commercial Grade Disinfectant & Cleaner – Patented formula kills 99.99% of germs, Herpes simplex virus, SARS-COV-1 and SARS-COV-2 (COVID-19). After application, Doxall™ provides ongoing antibacterial activity against Methicillin-resistant Staphylococcus aureus (MRSA) and Pseudomonas aeruginosa for up to 30 days.

 

The technology underpinning Doxall™ has been rigorously tested and verified by a number of independent laboratories and academic institutions. This includes testing by:

· National Institute of Allergy and Infectious Diseases (NIH, USA)

· Eurofins BioPharma (AU)

· Defence Science and Technology Group Department of Defence, Australian Government

· University of New South Wales

· La Trobe University, Bundoora

· Microchem Laboratory (USA)

 

For Further Information

Contact:

Brett Carter

CEO, Wintermute Biomedical & Ten Carbon Chemistry

M: +61 (0)416 454 588

w: doxall.com.au

 

About Wintermute Biomedical (wintermutebiomedical.com)

Founded in Montana USA in 2012 and until recently operating out of the R&D Precinct at La Trobe University in Melbourne, Wintermute Biomedical is a research organisation focussed on the development of next-generation therapeutic products. Wintermute research activity has been centred around solving some of the most pressing problems facing the world of heath care, namely antimicrobial resistance (AMR), cancer therapeutics, and topical solutions for skin infections.

About Ten Carbon Chemistry (tencarbon.com.au)

Developed in Australia and based on over a decade of research, Ten Carbon Chemistry's proprietary technology represents the next generation of sanitisation solutions that are designed to be highly effective and safe for you and our environment. Our novel science is grounded in utilising plant-based active ingredients that are found in common foodstuffs such as coconut oil and goats’ milk, but which have exceptional broad spectrum antipathogenic properties. Our technology has demonstrated activity against common pathogens like COVID-19, E. coli, Salmonella and MRSA, along with less common but potentially more lethal pathogens like Ebola, C. auris and Anthrax. This combination of an outstanding safety profile with exceptional broad spectrum antipathogenic activity allows us to develop products with numerous applications ranging from cleaning and sanitisation in food production to biowarfare protection. Ten Carbon Chemistry is an impact driven organisation and part of the profits derived from product sales will be directed into research for the development of new antimicrobial therapeutics to combat the rise of antimicrobial resistant superbugs; one of the greatest health challenges of our time.

Featured Products